TrialCurveKSCC1301: reconstructed Kaplan–Meier curves
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | BMC Cancer. 2021 Jan 5;21:23. doi: 10.1186/s12885-020-07766-5 |
|---|---|
| DOI | 10.1186/s12885-020-07766-5 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Disease-free survival — Full analysis set
From figure panel a · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: SOX not reached; mFOLFOX6 not reached. Survival at 18 months: SOX 85%; mFOLFOX6 82%. Hazard ratio mFOLFOX6 vs SOX 0.78 (95% CI 0.40–1.53).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SOX | 53 | 20 | not reached |
| mFOLFOX6 | 50 | 15 | not reached |
- mFOLFOX6 vs SOX: reconstructed HR 0.78 (95% CI 0.40–1.53)
Landmark survival (reconstructed)
| Time | SOX | mFOLFOX6 |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 88.7% | 91.8% |
| 18 mo | 84.9% | 81.6% |
| 24 mo | 81.1% | 77.6% |
| 36 mo | 69.1% | 73.4% |
| 48 mo | 54.8% | 68.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.808, reconstructed 0.782 pass
Overall survival — Full analysis set
From figure panel b · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: SOX not reached; mFOLFOX6 not reached. Survival at 18 months: SOX 96%; mFOLFOX6 96%. Hazard ratio SOX vs mFOLFOX6 0.77 (95% CI 0.21–2.86).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| SOX | 53 | 4 | not reached |
| mFOLFOX6 | 50 | 5 | not reached |
- SOX vs mFOLFOX6: reconstructed HR 0.77 (95% CI 0.21–2.86)
Landmark survival (reconstructed)
| Time | SOX | mFOLFOX6 |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 100.0% | 100.0% |
| 18 mo | 96.2% | 95.9% |
| 24 mo | 96.2% | 91.8% |
| 36 mo | 92.1% | 91.8% |
| 48 mo | 92.1% | 87.5% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.31, reconstructed 1.31 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/kscc1301-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/kscc1301-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: BMC Cancer. 2021 Jan 5;21:23. doi: 10.1186/s12885-020-07766-5 doi:10.1186/s12885-020-07766-5. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/kscc1301
Report a problem with these data
Related trials
- HIPECT4 (final analysis): Disease-free survival; Locoregional control; Overall survival
- BREAKWATER: Overall survival
- SCOT: Disease-free survival; Overall survival; Survival after recurrence (SAR)
- XELOX + bevacizumab ± adoptive cell immunotherapy in colorectal cancer: Overall survival; Progression-free survival
- Sequential vs upfront oxaliplatin in metastatic colorectal cancer: Overall survival
- SCOT (primary analysis): Disease-free survival; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials